Regeneron says Q3 results to be impacted by $100M IPR&D expense
syahrir maulana

Regeneron Pharmaceuticals (NASDAQ:REGN) said that its upcoming 2023 Q3 financial results will be negatively impacted by a $100M acquired in-process research and development charge.
The company said the expense is due to a milestone payment in the phase 1 ALN-APP program in early-onset Alzheimer's disease in its collaboration with Alnylam Pharmaceuticals (ALNY).


The charge is expected to negatively impact GAAP and non-GAAP diluted EPS by approximately $0.78.
Regeneron (REGN) is scheduled to report earnings on Nov. 2.


More on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals: Game-Changing Discoveries In Healthcare
Regeneron and Intellia expand gene editing partnership
Regeneron nabs FDA priority review for lymphoma therapy